A recent paper from Dr. Casey Mulligan examines the services that PBMs provide, estimating they create $145 billion in value to society annually. This value translates into a 7:1 return on investment each year.
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the Senate Special Committee on Aging hearing, “The Complex Web of Prescription Drug Prices, Part III: Examining Agency Efforts to Further Competition and
The Pharmaceutical Care Management Association recently submitted a letter to the Council of Economic Advisers. Click here for the letter PCMA’s letter includes the following points: 1. The report offers no evidence to back its claim that the drug marketplace
Unlocking an Affordable Future: Key #3 Support and Equip Clinicians ENHANCE PATIENT OUTCOMES AND IMPROVE THE PATIENT EXPERIENCE At the core of the pharmacy benefit specialty function lies expertise used to ensure the right patient gets the right drug in
A recent article (“The Corporate Scam that Even Trump Opposes: PBMs”) attacks the one industry that is both reducing prescription drug costs and improving quality: pharmacy benefit managers (PBMs). The White House fiscal year 2019 budget included many cost-saving items PBMs have
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Administration’s listening session on PBMs. “Today’s White House listening session on PBMs, where policymakers only hear from people and groups with vocal anti-PBM agendas, will
Bass Explains Opposition to Legislation, Risk of Drug Companies Lowering Rx Discounts On Wednesday, expert witnesses testifying before the U.S. House Committee on Energy & Commerce Subcommittee on Health highlighted the critical value pharmacy benefit companies provide for patients, employers, and
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the decision to raise Gleostine’s price from $50 to $768: “The drug company’s decision to raise the price of the forty-year-old drug Gleostine by 1400% –
©2024 PCMA. All Rights Reserved.
